|
|
X4 Pharmaceuticals Inc (NASDAQ: XFOR) |
|
*Market share is calculated based on total revenue.
News about X4 Pharmaceuticals Inc Contracts |
June 27, 2024
X4 Pharmaceuticals Achieves Remarkable Results in Ongoing Phase 2 Trial of Mavorixafor in Chronic Neutropenia, Initiates Pivotal Phase 3 CN TrialX4 Pharmaceuticals, a pioneer in the field of rare diseases, has recently announced positive interim clinical data from its ongoing six-month Phase 2 trial of Mavorixafor in patients with Chronic Neutropenia (CN). Additionally, the company has also initiated a pivotal Phase 3 trial in order to further assess the efficacy and safety of Mavorixafor in CN patients.The Phase 2 trial, which evaluated the use of once-daily oral Mavorixafor in combination with stable-dose G-CSF, has yielded promising results. The interim analysis of data from participants at the six-month ...
|
December 9, 2023
X4 Pharmaceuticals, a renowned biopharmaceutical company, recently presented additional data from the Phase 2 trial of their drug, Mavorixafor, at the ASH 2023 conference. The accumulated data continue to bolster the case for advancing Mavorixafor into a pivotal, global Phase 3 trial in specific chronic neutropenic disorders. With the company firmly on track to initiate the next phase in the first half of 2024, X4 Pharmaceuticals is poised to make significant strides in addressing the unmet needs of patients suffering from these conditions.
Chronic neutropenia is a rare blood disorder characterized by an unusually low count of neutrophils, a type of white blood cell essential for the immun...
|
Publicly Traded Peers of X4 Pharmaceuticals Inc
Allovir Inc
Share Performance
0.00%
30 Days
|
Allovir Inc
Profile
Allovir Inc's business model is centered around the development and commercialization of innovative cell therapies for patients with life-threatening viral diseases. They focus on utilizing advanced technologies to engineer allogeneic, off-the-shelf, and ready-to-use T cell therapies. By partnering with research institutions and leveraging strategic collaborations, Allovir aims to bring novel treatments to market and address unmet medical needs in the field of viral diseases.
More about Allovir Inc 's Market Share
|
Rigel Pharmaceuticals Inc
Share Performance
+96.57%
One Year
|
Rigel Pharmaceuticals Inc
Profile
Rigel Pharmaceuticals Inc is a biotechnology company that operates on a research and development business model. They focus on discovering, developing, and commercializing innovative small molecule drugs to address unmet medical needs. Their goal is to use their scientific expertise and strategic partnerships to bring new treatments to patients in various therapeutic areas.
More about Rigel Pharmaceuticals Inc's Market Share
|
Theriva Biologics inc
Share Performance
-66.64%
This Quarter
|
Theriva Biologics inc
Profile
Theriva Biologics Inc operates as a biotechnology company that focuses on the discovery, development, and commercialization of innovative and targeted therapies for various diseases. Their business model is centered around research and development, aiming to create new biologic drugs and bring them to the market to address unmet medical needs.
More about Theriva Biologics inc 's Market Share
|
Immunic Inc
Share Performance
-8.82%
This Year
|
Immunic Inc
Profile
Immunic Inc is a biotechnology company that focuses on developing and commercializing small molecule therapies for immune-related diseases. Their business model involves conducting research, clinical trials, and obtaining regulatory approvals, followed by marketing their products to healthcare providers and patients globally.
More about Immunic Inc 's Market Share
|
Aurinia Pharmaceuticals Inc
Share Performance
+62.66%
One Year
|
Aurinia Pharmaceuticals Inc
Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing therapies to treat autoimmune diseases such as lupus nephritis. Their business model revolves around conducting research and development to bring innovative medications to the market, securing partnerships and collaborations with other companies, and generating revenue through the sales of their products. By leveraging their expertise in the field, Aurinia aims to improve the lives of patients suffering from these diseases and achieve financial success through the commercialization of their therapies.
More about Aurinia Pharmaceuticals Inc 's Market Share
|
Zymeworks Inc
Share Performance
0.00%
30 Days
|
Zymeworks Inc
Profile
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
More about Zymeworks Inc 's Market Share
|
Sio Gene Therapies Inc
Share Performance
0.00%
This Year
|
Sio Gene Therapies Inc
Profile
Sio Gene Therapies Inc operates with a business model focused on developing and commercializing gene therapies to treat and potentially cure various neurological genetic diseases. Their approach involves leveraging cutting-edge gene therapy technology to address unmet medical needs and improve patients' quality of life.
More about Sio Gene Therapies Inc 's Market Share
|
Longboard Pharmaceuticals Inc
Share Performance
+138.84%
This Year
|
Longboard Pharmaceuticals Inc
Profile
Longboard Pharmaceuticals Inc is a biotechnology company focused on the discovery and development of therapies for neurological disorders. Their business model revolves around conducting comprehensive research, identifying promising drug candidates, and advancing them through preclinical and clinical trials. With a focus on innovative approaches and strategic partnerships, Longboard aims to ultimately bring safe and effective treatments to patients in need.
More about Longboard Pharmaceuticals Inc 's Market Share
|
Greenlight Biosciences Holdings Pbc
Share Performance
-30.32%
This Quarter
|
Greenlight Biosciences Holdings Pbc
Profile
Greenlight Biosciences Holdings Pbc's business model focuses on using proprietary cell-free bioprocessing technology to produce sustainable and environmentally friendly bio-based products.
More about Greenlight Biosciences Holdings Pbc's Market Share
|
Fresh Tracks Therapeutics Inc
Share Performance
0.00%
This Quarter
|
Fresh Tracks Therapeutics Inc
Profile
Fresh Tracks Therapeutics Inc is a biotechnology company that focuses on developing innovative therapies for various diseases. Their business model revolves around conducting research and development to discover new drug candidates, conducting clinical trials to test their effectiveness, and ultimately bringing these therapies to market through partnerships or direct sales. They aim to monetize their discoveries through licensing agreements, product sales, and collaborations with other pharmaceutical companies.
More about Fresh Tracks Therapeutics Inc 's Market Share
|
Ikena Oncology Inc
Share Performance
0.00%
30 Days
|
Ikena Oncology Inc
Profile
Ikena Oncology Inc's business model focuses on developing innovative cancer therapies through targeted drug discovery and development.
More about Ikena Oncology Inc 's Market Share
|
C4 Therapeutics Inc
Share Performance
+35.40%
This Quarter
|
C4 Therapeutics Inc
Profile
C4 Therapeutics Inc operates on a business model that focuses on developing novel therapies using their proprietary Degronimid? platform, designed to selectively target and degrade disease-causing proteins. This approach potentially offers a new avenue for treating various diseases by harnessing the body's natural protein degradation machinery.
More about C4 Therapeutics Inc 's Market Share
|
Curis Inc
Share Performance
-56.60%
This Year
|
Curis Inc
Profile
Curis Inc's business model revolves around the development and commercialization of innovative cancer therapies. They focus on discovering and advancing drug candidates targeting specific molecular pathways involved in cancer growth and survival. The company collaborates with pharmaceutical partners to conduct clinical trials and seek regulatory approval for their products.
More about Curis Inc 's Market Share
|
Inhibrx Biosciences Inc
Share Performance
+94.24%
This Quarter
|
Inhibrx Biosciences Inc
Profile
Inhibrx Inc operates using a business model that focuses on the development and commercialization of therapeutics. The company leverages its innovative technology platform to create a diverse pipeline of biologics for the treatment of various diseases. Inhibrx Inc aims to collaborate with strategic partners to advance the development of its pipeline and expand its reach in the healthcare market.
More about Inhibrx Biosciences Inc 's Market Share
|
Biolinerx Ltd
Share Performance
0.00%
30 Days
|
Biolinerx Ltd
Profile
Biolinerx Ltd is a biopharmaceutical company that focuses on discovering, developing, and commercializing novel therapeutics for various diseases. Their business model revolves around the research and development of innovative drug candidates, conducting clinical trials to assess their safety and efficacy, and obtaining regulatory approvals to bring these treatments to market. They aim to generate revenue through licensing agreements, strategic collaborations, and the sale of their therapeutics to patients or healthcare providers.
More about Biolinerx Ltd 's Market Share
|
Glycomimetics Inc
Share Performance
-40.30%
One Year
|
Glycomimetics Inc
Profile
Glycomimetics Inc is a biopharmaceutical company that utilizes its expertise in carbohydrate chemistry to develop novel drug candidates. Their business model involves researching and developing proprietary glycomimetic compounds that can target specific disease pathways. They then collaborate with pharmaceutical partners to further develop and commercialize these potential therapeutics.
More about Glycomimetics Inc 's Market Share
|
Sources: X4 Pharmaceuticals Inc and all companies mentioned above in this report
|
